Form 4: Cardiff Oncology CFO James E. Levine Reports Stock Option Grant

James E. Levine, CFO of Cardiff Oncology, reports the acquisition of 205,008 stock options with an exercise price of $3.51, vesting over four years.

Summary

• James E. Levine, the Chief Financial Officer of Cardiff Oncology, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 7, 2024.
• Levine acquired 205,008 stock options with an exercise price of $3.51.
• These options vest over time, with 25% vesting on March 7, 2025, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• Following the reported transaction, Levine directly owns 962,496 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a standard practice.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The vesting schedule is typical for executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation in the biotech industry, often used to attract and retain talent.
• Vesting schedules, like the one described (25% after one year, then monthly), are common to ensure long-term commitment.
• Comparing the size of the grant (205,008 options) to grants at similar-sized biotech companies would require further research into executive compensation benchmarks.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
• Employees may see it as a positive sign of the company's commitment to its leadership.

Key Dates